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Abstract
Background:  Genetic make up had been known to influence pharmacokinetics and
pharmacodynamics of psychotropic medications. Time separation in evolutionary trend in Africans,
Orientals and Caucasians had been thought a possible explanation for the observed racial variation
in activities of Cytochrome P 450 (CYP 450) enzymes, which are responsible for metabolism of
psychotropic and other medications in human. Past studies on pharmacokinetics and
pharmacodynamics of antipsychotic medications and socio-cultural factors influencing response to
antipsychotic medications had consistently giving an inkling of possible racial difference in symptoms
response to antipsychotic medications. Another growing body of evidence subscribing to possible
racial difference in psychotic symptoms response to antipsychotic medications is the observed
variation in antipsychotic medications prescription pattern and dosage across races and regions.
Empirical observation had shown that dosage prescription pattern of antipsychotic medications in
most Sub-Saharan African countries deviates from the standard prescription guidelines published
for use in western parts of the world. Studies coming from the United States (U.S) had consistently
reported a higher dosage of antipsychotic medications prescription for African-American patients
compared to their Caucasian counterparts. Research on East Asia Psychotropic Prescription
(REAP) study had also identified high dosage antipsychotic medications prescription pattern well
above the recommended dose of 1,000 mg Chlorpromazine equivalent per day as common
practices in some East Asian countries.
Presentation of the Hypothesis: The pertinent question is why the apparent differences in
dosage prescription practices across races and regions? The possibility of racial differences in
psychotic symptoms response to antipsychotic medications rather than clinicians' prescription
attitudes was entertained.
Testing the Hypothesis: Future carefully controlled studies might be needed to test the
proposed hypothesis of racial differences in psychotic symptoms response to antipsychotic
medications.
Implication of the Hypothesis: There might be actual racial influence on psychotic symptoms
response to antipsychotic medications. If future carefully controlled studies uphold the hypothesis
of racial differences in psychotic symptoms response to antipsychotic medications, there might be
need to draw up new treatment or prescription guidelines that would put into consideration
variations in genetic make up and consequent racial differences in psychotic symptoms response to
antipsychotic medications.
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Background
Genetic make-up had been known to influence metabo-
lism and utilization of psychotropic medications [1-4].
Genetic and environmental factors also determined the
phenotypic inter-racial differences worldwide. Earlier
studies had documented racial variation in metabolism of
antipsychotic medications based on serum level measure-
ment of the medications and other parameters [5,6]. The
findings of these studies [5,6] could be due to racial differ-
ences in activities of cytochrome P 450 (CYP 450)
enzymes, especially CYP2D6 and CYP2C19 which are
largely responsible for metabolism of antipsychotic med-
ications and other psychotropic drugs [1-4]. Another pos-
sible factor that could be responsible for racial variation in
serum level of antipsychotic medications and other
parameters of psychotic symptoms response is individual
variation in dopamine receptor occupancy of antipsy-
chotic medications which had been documented [7].
In the past two decades, review of literature on pharma-
cokinetics and pharmacodynamics of psychotropic medi-
cations and socio-cultural influences on response to
psychotropic medications in different races had consist-
ently pointed an exploratory search light at possible vari-
ation in racial symptoms response to psychotropic
medications [8-10]. Various determinants ranging from
biological to socio-cultural factors had been proposed as
explanations for the often observed racial difference in
metabolism and response to psychotropic medications
[10]. Aside the biological and socio-cultural explanations
put forward by these reviews as regards psychotropic med-
ications in general [10], variation across races and ethnic-
ity in the prescription pattern and dosage of antipsychotic
medications is another growing body of evidence sub-
scribing to the possible existence of variation in racial or
ethnic symptoms response to antipsychotic medications
in particular.
Prescription pattern and dosages of antipsychotic medica-
tions prescribed varies from one patient to another, from
one professional to another, from one clinical institution
to another and from one region to another [11]. Empirical
observation and few studies available in Nigeria [12,13]
had shown that antipsychotic prescription pattern and
dosages of antipsychotic medications prescribed in Sub-
Saharan Africa deviate from the prescription guidelines
published for use in western parts of the world [14,15].
High dosage of antipsychotic medications are often pre-
scribed in Sub-Saharan Africa and use of depot antipsy-
chotic medications are common [13], when compared to
recommendations in prescription guidelines published
for standard psychiatric practice in western countries of
the world [14,15].
It had also been found that African-Americans compared
to their Caucasian counterparts often received antipsy-
chotic medications for a longer period of time as mainte-
nance treatment for Bipolar Affective Disorders (BAD)
[16,17]. Both studies [16,17] could not adduce any partic-
ular reason for this difference between African-American
patients and their Caucasian counterparts. Walkup et al
[18] also found that African-Americans were more likely
to be prescribed higher dose of antipsychotic medications
than the recommended dosage (a dose greater than 1,000
mg Chlorpromazine equivalent per day), they concluded
that there was a tendency for minority individuals to be
prescribed higher dosage of antipsychotic medications in
excess of the recommended range. Diaz and De Leon [19]
had found that the odd of being prescribed excessive
doses of typical and high potency antipsychotic medica-
tions is about two times higher for African-American than
Caucasian patients with schizophrenia.
Presentation of the hypothesis
Hypothesis of racial differences in effective therapeutic 
dosage of antipsychotic medications in treating psychotic 
symptoms
The reasons for the difference between the prescription
pattern in African-American and their Caucasian counter-
parts in above studies [16-18] could not be adequately
explained and the observation that minority individuals
were likely to be prescribed higher doses of antipsychotic
medications did not give a satisfactory answer to why the
difference?
Therefore, a possible explanation is that at the same level
of severity of psychotic symptoms as measured by any
standardized rating scale, African-Americans and black
Africans of Sub-Saharan African descent might require a
higher dosage of antipsychotic medications compared to
their Caucasian counterparts for resolution of their psy-
chotic symptoms. This difference may lie in varied phar-
macogenetic effects in metabolism and utilization of
antipsychotic medications in different races of the world.
The argument of racial differences as it affects the effective
therapeutic dosage of antipsychotic medications in treat-
ment of psychosis is given a further weight by Sim et al
study [20], which reported higher dosage of antipsychotic
medications prescription pattern in East Asian countries,
especially Japan, Korea and Singapore.
There is need to explore the possible explanations for the
apparent racial and regional differences in dosage pre-
scription pattern of antipsychotic medications.
Differences in prescribing practices
It had already been noted that prescribing practices might
vary from one professional to another and from oneBMC Research Notes 2008, 1:25 http://www.biomedcentral.com/1756-0500/1/25
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region to another [11]. This may be because of variation
in training background of individual mental health pro-
fessionals. It may also be differing practices in different
regions of the world which had come to stay because of
empirical observation in practice over a long period of
time that symptoms resolution of psychosis are delayed or
unachievable when the recommended guide lines are
strictly adhered to. This may be the possible picture of sit-
uation in Sub-Saharan African countries where empirical
observation had shown higher dose of antipsychotic med-
ications prescription among mental health professionals
compared to the western world.
The possible argument against differences in prescribing
practices being a function of training background could
be found in literature coming from the United States
(US), where training of mental health professionals is reg-
ulated by a uniform body and can be presumed to be a
uniform training background. In these literatures [16-18],
it had been consistently found that African-American are
likely to be placed on higher dose of antipsychotic medi-
cations and are likely to take same as maintenance medi-
cations over a longer period of time compared to their
Caucasian counterparts. It could also be argued that the
relative higher dosage of antipsychotic medications being
prescribed in African-Americans compared to their Cauca-
sian counterparts is borne out of a long standing practic-
ing norms derived from empirical observations, which
had not been subjected to evidence based practice
approach through carefully controlled studies.
Therefore, the significant difference in dosage prescription
pattern and longer term use of antipsychotic medications
observed in African-Americans and black Africans in Sub-
Saharan Africa compared to their Caucasian counterparts
may not be solely explained by variation in training back-
grounds of attending mental health professionals in these
regions of the world.
Socio-cultural acceptability and unacceptability of the 
presenting psychotic symptoms
Socio-cultural acceptability of patients with symptoms of
mental illness may vary according to symptoms presenta-
tion. Patients with depressive symptoms are likely to be
more accepted and coped with than patients that present
with psychotic symptoms, while patients that present
with psychotic symptoms without aggression are tend to
be more accepted and coped with than patients that
present with psychotic symptoms and aggression.
The socio-cultural acceptability and unacceptability of
patients' symptoms affect directly and indirectly the pre-
scription pattern and practices. Famuyiwa [12] noted that
there was tendency for patients with depression to be
under treated or under medicated, possibly because of
high acceptability of these patients compared to those pre-
senting with psychotic symptoms. Sim et al [20] had iden-
tified aggression as an important factor positively
associated with high dosage prescription of antipsychotic
medications in East Asian region. The relevance of socio-
cultural acceptability and unacceptability of symptoms
presentation as it affects prescription practices is further
highlighted from the report of Barbui et al study [21], who
found that positive symptoms presentation in patients
with schizophrenia was positively associated with high
antipsychotic dose prescription, whereas negative symp-
toms presentation was negatively associated with high
antipsychotic dose prescription above recommended pre-
scription guidelines.
Relating Barbui et al [21] findings to the findings of Diaz
and De Leon [19] who found that the probability of being
prescribed high dose and high potency antipsychotic
medications was about two times higher for African-
Americans than for Caucasian patients with schizophre-
nia, one would be tempted to ask whether African-Ameri-
cans are likely to present with more florid positive
symptoms of schizophrenia compared to their Caucasian
counterparts. Another plausible explanation is that Afri-
can-American patients presenting with psychotic symp-
toms were usually assessed to be more potentially
aggressive and dangerous compared to their Caucasian
counterparts. These two possibilities may be able to
explain the apparent difference in antipsychotic medica-
tion dosage prescription pattern for African-Americans
and their Caucasian counterparts.
Then, the zeal to curtail aggression and potential danger-
ousness in a patient presenting with psychotic symptoms
may be the reason behind the dosage prescription of
antipsychotic medication well above the recommenda-
tion in standard prescription guidelines. This may also
explain poly-pharmacy and common use of depot antip-
sychotic medications among African-American and black
African patients from sub-Saharan Africa that had been
noted in some studies [13,18-21].
Hypothesis of racial differences in psychotic symptoms 
response to antipsychotic medications
Another possible explanation for differences in dosage
prescription pattern of antipsychotic medications that
had been found in the above studies [11,13,16-21] is
racial differences in psychotic symptoms response to vari-
ous antipsychotic medications.
Having been established that genetic variation have some
influence on pharmacodynamics and pharmacokinetics
of psychotropic medications [1-4], there are possibilities
that racial differences in genetic make-up may influenceBMC Research Notes 2008, 1:25 http://www.biomedcentral.com/1756-0500/1/25
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the effective therapeutic response to dosage of antipsy-
chotic medications.
The deviation in dosage prescription practices from pre-
scription guidelines published for use in western parts of
the world [14,15] in most Sub-Saharan African countries
and the consistent findings of studies coming from the
United States [11,16-19,21,22], that documented high
dosage prescription of antipsychotic medications among
African-American patients compared to their Caucasian
counterparts and also the study by Sim et al [20] coming
from East Asia give some support to the hypothesis that
racial differences in psychotic symptoms response to
antipsychotic medications might be responsible for the
apparent difference in dosage prescription practices.
Although, Diaz and De Leon [19] were quick to conclude
that pharmacogenetic differences were unlikely to explain
the significant racial difference in dosage prescription pat-
tern of antipsychotic medications found in their study and
adduced reason for their finding to clinicians' attitude.
However, the argument that clinicians' attitude could be
responsible for their finding need to be subjected to fur-
ther challenge in the presence of growing body of evi-
dence supporting biological and socio-cultural
determinants for possible ethnic or racial difference in
response to psychotropic medications [1-4,8-10]. This
would explain why the authors themselves [19] recom-
mended pharmacogenetic testing in future studies to
unravel the reason for their finding which had been con-
sistently replicated by other studies [11,16-18,21,22].
Testing the Hypothesis
Considering the presence of other confounding factors
like availability and cost of antipsychotic medications,
health care financing systems among other factors which
may vary in different regions of the world and can contrib-
ute to the observed difference in prescription pattern and
dosage of antipsychotic medications across races and
regions, the need for further studies is apparent to confirm
or refute the hypothesis of racial difference in psychotic
symptoms response to antipsychotic medications. These
studies would be necessary to unravel the actual reason
behind the observed difference in dosage of antipsychotic
medication prescription that existed among black Afri-
cans, African-Americans, Orientals and their Caucasian
counterparts. Controlled studies, utilizing pharmacoge-
netic testing, standardized psychotic symptoms resolution
assessment method and serum level measurements of
antipsychotic medications during treatment might be able
to provide a definitive answer to the puzzling question of
observed differences in dosage of antipsychotic medica-
tion prescription across races and regions. Actual racial
differences in psychotic symptoms response to antipsy-
chotic medications due to genetic variations might be the
underpinning factor.
Implication of the Hypothesis
If the hypothesis of racial differences in psychotic symp-
toms response to antipsychotic medications is upheld by
future studies, there might be need to draw up new pre-
scription or treatment guidelines that would take into
consideration variations in genetic make-up and conse-
quent racial differences in psychotic symptoms response
to antipsychotic medications.
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